Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-02
2007-10-02
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S002600
Reexamination Certificate
active
10559155
ABSTRACT:
It is an object of the present invention to provide an excellent enhancer for an osteogenesis accelerator that can enhance the activity of BMP as an osteogenesis accelerator. Another object of the present invention is to provide a method of screening for a novel enhancer for an osteogenesis accelerator.The present invention relates to an enhancer for an osteogenesis accelerator, which comprises a compound having a TGF-β selective inhibitory activity as an active ingredient, the enhancer being administered with an osteogenesis accelerator containing BMP as an active ingredient either simultaneously or sequentially, and to a method of screening for an enhancer for an osteogenesis accelerator, comprising using a TGF-β inhibition as a measure for discovering the enhancer.
REFERENCES:
patent: 5393739 (1995-02-01), Bentz et al.
patent: WO 00/61576 (2000-10-01), None
patent: WO 02/22871 (2002-03-01), None
Fecik et al., “The Search for Orally Active Medications Through Combinatorial Chemistry”, Res. Rev., 18, No. 3, 149-185, 1998.
Kunio Takaoka, Tominaga Shimizu, “BMP ni yoru Hone Saisei to Kotsu Soshosho,” Igaku no Ayumi, 2001, vol. 198, p. 625-629.
Spinella-Jaegle, S. et al., Opposite effects of bone morphogenetic protein-2 and transforming growth factor-beta1 on osteoblast differentiation, Bone, 2001, vol. 29, No. 4, p. 323-330.
Shingo Maeda, Kenji Imamura, Kohei Miyazono, “TGF-beta/BMP Signal to Kotsuga Saibo Bunka,” Experimental Medicine, 2002, vol. 20, No. 17 (Zokan), p. 101-106.
Inman, Gareth J. et al., SB-431542 is a potent and specific inhibitor of transforming grown factor-beta superfamily type I activin receport-like kinase (ALK) recepotrs ALK4, ALK5, and ALK7, Molecular Pharmacology, 2002, vol. 62, No. 1, pp. 65-74.
S. Maeda, et al., Endogenous TGF-Beta Signaling Suppresses Maturation of Osteoblastic Mesenchymal Cells, The EMBO Journal, 2004, vol. 23, No. 3, 552-563.
Imamura Takeshi
Maeda Shingo
Miyazono Kohei
Diebner Gerard F.
Dreier LLP
Henley III Raymond J.
Nippon Shinyaku Co. Ltd.
LandOfFree
Osteogenesis-promotion enhancer and method of screening the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Osteogenesis-promotion enhancer and method of screening the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Osteogenesis-promotion enhancer and method of screening the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3827287